Advanced Search

Display
per page
  Report Title Date Provider Type Pgs Price

ADMA Biologics Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.

This report is essential reading for any serious investor, providing comprehensive financial information on a company's perfo...

19 Apr 2014 Reuters Investment Profile 12 $20.00

Wright Investors Service Comprehensive Report for Adma Biologics Inc

Quantitative analyses of financial statements (Income Statement, Balance Sheet and Sources of Capital), extensive ratio table...

24 Apr 2014 Wright Reports 38 $75.00

ADMA: 4Q13: 2014 will be the key year with major catalyst toward year-end; reiterating Buy rating and a 12-month price target of $15.00

ADMA reported 4Q13 financial results with a net loss of ($4.7MM), or ($0.55) net loss per share. For the 2014 full year, net...

01 Apr 2014 Laidlaw & Company 8 $25.00

ADMA: Continued confidence after recent management update; reiterating Buy rating and a 12-month price target of $15.00

After a recent company update by ADMA management, we walked away with renewed confidence as all the company’s development pla...

27 Jan 2014 Laidlaw & Company 8 $25.00

ADMA: RSV Prevention and Treatment in Immune-compromised Patient; initiation with a Buy rating and a 12-month price target of $15.00

With a modest hurdle for approval, substantial unmet need, limited competition and robust Phase II and real world use clinica...

21 Nov 2013 Laidlaw & Company 32 $75.00

Company Snapshot - Adma Biologics Inc

Four Directors at Adma Biologics Inc bought 108,939 shares at 8.500USD. The significance rating of the trade was 73/100. Is ...

24 Oct 2013 Directors Deals Ltd. 1 $12.00